& Abstract: Tapentadol prolonged release (PR) for the treatment of moderate to severe chronic pain combines 2 modes of action. These are l-opioid receptor agonism and noradrenaline reuptake inhibition in a single molecule that allow higher analgesic potency through modulation of different pharmacological targets within the pain transmitting systems. At the same time, this can also serve as a clue for modulation of different pain-generating mechanisms according to nociceptive, neuropathic, or mixed pain conditions. Tapentadol PR has now been on the market for 5 years, with over 4.6 million people treated worldwide. A panel of pain specialists convened in Germany to review the clinical program and to discuss the role of tapentadol PR in the management of chronic pain. The clinical study program demonstrated effective and generally well-tolerated treatment for up to 2 years in a broad range of chronic pain conditions, including those with neuropathic pain components. This was confirmed in routine clinical practice observations. Head-to-head studies with World Health Organization (WHO) III opioids such as oxycodone controlled release and oxycodone/naloxone PR showed at least comparable pain relief in the treatment of moderate-tosevere musculoskeletal pain. Rotation from poorly tolerated WHO III opioids to tapentadol PR provided effective pain relief and better symptom control for musculoskeletal pain compared to previous medication. Functionality, health status and quality of life also improved under tapentadol PR treatment. The gastrointestinal tolerability profile was more favorable compared to other tested WHO III opioids. Tapentadol PR has a good safety profile and no evidence of acquired tolerance from the long-term data so far collected. Overall, tapentadol PR represents an effective and generally well-tolerated alternative to "classical" opioidergic drugs. &
INTRODUCTION
An average of 27% of the general adult population in the European Union is affected by chronic pain 1 ; in the United States, the prevalence is greater than that of diabetes, heart disease, and cancer combined. 2 Chronic pain was rated severe by 34% of respondents to a European telephone survey and constant by 46% 3 ; 40% considered their pain management not adequate. 3 Restrictions in daily activities, social life and working activities, sleep disturbances, anxiety, and depression are frequently reported; the impact on patients' functioning in daily life, their overall well-being, and quality of life is thus substantial. The burden on society is also high and includes considerable healthcare and welfare costs, as well as indirect costs such as loss of productivity and skills due to absenteeism and early retirement. 4, 5 A 1-year follow-up of incidences of chronic postsurgical pain with a numeric rating scale (NRS) pain intensity score of ≥ 3 (mainly trauma/orthopedic surgery) found that all patients in the category "laborer" reported chronic pain, showing the immense burden on work productivity. 6 Chronic pain management is often complex and clinically challenging, requiring a multimodal treatment approach. Pain can be nociceptive (resulting from tissue damage or inflammation), neuropathic (resulting from damage to the peripheral or central nervous system), or both (mixed pain). For the pharmacological treatment of moderate-to-severe chronic pain (postsurgery, posttrauma, cancer, and other specific indications), opioids are an established standard. However, this medication class is associated with significant gastrointestinal and central nervous system (CNS) side effects, which might influence adherence to treatment or result in treatment discontinuation. 7 To achieve sufficient pain reduction, patients might require the prescription of 2 drugs targeting different pain mechanisms either as comedications or as a fixed-dose formulation, which carries the risk of drug-drug interactions and increased side effects. Thus, it is often difficult to find the right balance between effective analgesia avoiding undertreatment and adequate tolerability. Combining more than 1 mechanism of action in a single molecule might avoid these disadvantages. The centrally acting analgesic tapentadol was developed to improve the therapeutic range of opioids by adding a different, complementary mode of action. It combines l-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI) 8 and has been proposed as the first representative of a new pharmacological class of drugs, the MOR-NRI. 9 The MOR mechanism interrupts pre-and postsynaptic transmissions of ascending pain signals in the spinal cord and supraspinally activates the descending inhibitory projections. 10 It is primarily effective against moderate-to-severe acute pain. NRI increases noradrenaline concentrations in the synaptic cleft and thus enhances the body's pain inhibition in the descending pathways. NRI drugs are particularly useful in chronic neuropathic pain conditions. 10 As both mechanisms contribute to the analgesic effect, the inclusion of NRI reduces the "opioid load" and might thus mitigate side effects associated with opioid use. 8 Synergistic interaction regarding analgesia between the 2 modes of action allows for strong analgesic effects despite the relatively moderate activity at the 2 target sites (for detailed information regarding the MOR-NRI concept, see Tzschentke et al. 10 ). The dual mode of action indicates suitability for a broad range of pain conditions, in particular, whenever a neuropathic pain component cannot be excluded.
The prolonged release (PR) formulation of tapentadol was developed for the treatment of moderate-to-severe chronic pain for twice daily dosing and is a scheduled narcotic substance in most European countries and in the United States. It has been assessed in an extensive clinical program including approximately 12,000 patients as well as in several observational studies in routine clinical practice with over 10,000 patients since its launch in Europe in 2010 and the United States in 2011. Tapentadol PR is indicated in Europe "for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics." 11 In the United States, it is approved for the treatment of adults with pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. 12 Moreover, in the United States, it is explicitly indicated for the management of painful diabetic peripheral neuropathy (DPN). 12 As tapentadol PR has now been on the market for 5 years with over 4.6 million people treated worldwide, a review of the clinical program and discussion of its role in the management of chronic pain by a panel of experienced pain specialists seemed appropriate.
CLINICAL PROGRAM

This chapter presents the European and U.S. clinical development program for tapentadol PR and describes the clinical phase 3 trials undertaken for European Medicines
Tapentadol Prolonged Release for Chronic Pain 679 Agency (EMA) and U.S. Food and Drug Administration (FDA) approval of the medication as well as additional investigations in specific patient populations.
Phase 3 Studies
To obtain regulatory approval from both the EMA and FDA for tapentadol PR for the broad label "severe chronic pain," 5 clinical phase 3 trials studying patients with typical osteoarthritis (OA) pain, 13, 14 low back pain (LBP), 14, 15 or DPN 16 were carried out (Table 1) . Three studies (OA pain, 13 LBP, 15 and ClinicalTrials.gov identifier NCT00486811 [OA pain]) shared the same double-blind, randomized (1:1:1), placebo-and oxycodone controlled release (CR)-controlled design with 3-week titration and 12-week controlled dose adjustment maintenance phase (twice daily tapentadol PR doses 100 to 250 mg). The dosing ratio for tapentadol PR vs. oxycodone CR was 5:1 and was based on preclinical studies. 13 Two primary efficacy parameters were assessed to fulfill requirements of different regulatory bodies: change in pain intensity (measured on an 11-point NRS) from baseline at week 12 of the maintenance period (U.S. regulation) and change in pain intensity from baseline for the overall maintenance period (regulation for Europe and other countries). The last observation carried forward (LOCF) approach was used to impute missing values after early treatment discontinuation. The majority of patients (> 80%) presented with severe chronic pain (NRS ≥ 6). In the first study, both tapentadol PR and oxycodone CR demonstrated significantly better reductions in OA pain intensity than placebo throughout the maintenance period (but not at week 12 for oxycodone CR). 13 At week 12, the proportion of patients with ≥ 30% reduction in pain intensity from baseline was not significantly different between tapentadol PR and placebo (43% vs. 35.9%; P = 0.058) but significantly lower for oxycodone CR than placebo (24.9% vs. 35.9%; P = 0.002). Compared to placebo, significantly more patients attained ≥ 50% pain relief under tapentadol PR (32% vs. 24.3%; P = 0.027) but not under oxycodone CR (17.3% vs. 24.3%). The latter analysis, however, was affected by the higher early discontinuation rate of patients in the oxycodone CR group, which was in part due to the higher rate of gastrointestinal side effects for oxycodone CR (67.3% vs. 43% for tapentadol PR). This study was carried out in North America, Australia, and New Zealand. A second OA study conducted at sites in Europe (ClinicalTrials.gov identifier NCT00486811; scheduled for publication) was unable to achieve similar results on the primary efficacy endpoints (change in pain intensity at week 12 and for the overall maintenance period). The third study included LBP patients and showed significant differences to placebo for both analgesics (P < 0.001). 15 In contrast to oxycodone CR (23.3% vs. 18.9% with placebo; P = 0.174), the proportion of patients achieving ≥ 50% pain relief was significantly higher with tapentadol PR than with placebo (27% vs. 18.9%; P = 0.016). In all three studies, gastrointestinal problems occurred more frequently with oxycodone CR than with tapentadol PR. The odds of experiencing constipation or nausea/vomiting were significantly lower for tapentadol PR compared to oxycodone CR (for both comparisons, P < 0.001). 15 Significant changes in quality of life over the treatment period compared to placebo were observed in the first of the OA studies 13 for tapentadol PR in the EuroQoL-5Dimension (EQ-5D) 17 health survey (least squares [LS] mean difference 0.05; P = 0.004) and the physical component score of the Short Form-36 (SF-36) 18 health survey (LS mean difference 2.8; P < 0.001), and for oxycodone CR in the SF-36 mental component score (LS mean difference À3.0; P < 0.001). Both the EQ-5D and SF-36 physical component score significantly improved under both analgesics compared to placebo in LBP patients. 15 A phase 3 study with randomized withdrawal design provided evidence for the efficacy of tapentadol PR in the treatment of painful DPN. 16 Patients with type 1 or type 2 diabetes mellitus and painful DPN for ≥ 6 months with an average pain intensity score of ≥ 5 (NRS) were titrated to their optimal tapentadol PR dose in a 3-week open-label phase. Patients responding to treatment (≥ 1-point improvement in their average pain intensity) were then randomly allocated to either tapentadol PR or placebo for a 12-week, double-blind, fixed-dose maintenance phase. The tapentadol dose was 100 to 250 mg twice daily. The primary efficacy endpoint was the change in pain intensity during the double-blind phase. Pain relief attained during titration was maintained under 12-week tapentadol PR treatment and declined under placebo treatment, with significant differences between the 2 groups (LS mean difference À1.3 [95% confidence interval (CI) À1.7 to À0.92]; P < 0.001; LOCF). Significantly more patients in the tapentadol PR group reached clinically relevant pain relief (≥ 50%). The most common treatment-emergent adverse events (TEAEs) leading to treatment discontinuation were gastrointestinal and nervous system disorders. Under tapentadol maintenance treatment, nausea, anxiety, diarrhea, and dizziness were most frequently documented. A second study with a similar design confirmed these results (see Table 1 ). 19 Pain relief was significantly better under tapentadol PR than under placebo treatment (LS mean difference À0.95 [95% CI À1.42 to À0.49]; P < 0.001; LOCF) with a higher proportion of patients with at least 50% improvement (40.4% vs. 28.9%; P = 0.015). The most common side effects during double-blind tapentadol PR treatment were nausea (21.1%) and vomiting (12.7%).
Long-term safety and tolerability of tapentadol PR (100 to 250 mg twice daily) were compared to oxycodone CR in an open-label, randomized (4:1) phase 3 trial in patients with moderate-to-severe chronic knee or hip OA pain or LPB.
14 Both analgesics provided sustained pain relief for up to 1 year (LOCF approach), but tapentadol PR was associated with better gastrointestinal tolerability than oxycodone CR, and time to treatment discontinuation was significantly longer. There was no evidence that tapentadol PR was associated with acquired tolerance. In tapentadol patients who completed the study (46% of all patients in the tapentadol arm), mean weekly pain intensity rapidly decreased from 7.6 at baseline over the first 4 treatment weeks, with sustained pain relief for the remainder of the study (pain intensity scores between 3.5 and 3.9). Following dose titration, daily tapentadol PR doses remained relatively stable at 390 mg for the remainder of the study. Patients with chronic OA pain or LBP who completed one of the 3 studies described above [13] [14] [15] or a 7-week, randomized, double-blind, crossover tapentadol dose conversion study 20 were included in a phase 3, openlabel, 1-year extension study with tapentadol PR (Table 2) . 21 Mean pain relief obtained under previous treatment (placebo, tapentadol PR, or oxycodone CR) was maintained during the extension year (from 3.9 AE 2.4 points at baseline to 3.7 AE 2.4 points at study end; LOCF); previous improvements in quality of life were also sustained. The most frequently reported side effects were headache (13.1%), nausea (11.8%), and constipation (11.1%). To assess the development of tolerance, data of the 249 patients who entered the extension study after receiving tapentadol PR for a year in the long-term tolerability study 14 were separately analyzed. The majority of these patients (75.9%) completed the extension period and thus received tapentadol treatment for 2 years. After the initial titration period, pain intensity ( Figure 1 ) and mean daily tapentadol PR doses remained relatively stable over the 2-year period, which suggests that there was no acquired tolerance associated with tapentadol PR treatment for up to 2 years. Efficacy and tolerability of tapentadol PR was further demonstrated in a phase 3 clinical trial comparing tapentadol PR with morphine CR in the treatment of moderate-to-severe cancer-related pain (see Table 2 ). 22 The study employed a randomized withdrawal design for the 4-week maintenance phase; noninferiority comparison of tapentadol PR to morphine CR was therefore limited to the 2-week double-blind titration period. Tapentadol PR was found noninferior to morphine CR based on responder rates at the end of the titration. During maintenance, the odds ratio of being a responder under tapentadol PR compared to placebo was 2.02 (95% CI 1.12, 3.65; P = 0.02). Incidences of nausea (12.4% vs. 24.1% for morphine; P = 0.0012), vomiting (5.3% vs. 15.8%; P = 0.0002), and dry mouth (1.2% vs. 6.3%; P = 0.0039) were significantly lower for tapentadol PR than morphine CR during titration.
In summary, evidence from phase 3 clinical trials suggests good efficacy and tolerability of tapentadol PR in the management of moderate-to-severe chronic OA pain, LBP, painful DPN, and cancer-related pain. Efficacy was at least comparable to oxycodone CR and morphine CR and could be sustained over a 2-year treatment period. Tapentadol PR was associated with better gastrointestinal tolerability than the 2 WHO III opioids.
Phase 3b and 3b/4 Studies
The efficacy of tapentadol PR in the management of chronic pain was further investigated in specific study populations (previous inadequate treatment with WHO I or WHO II analgesics, rotation from prior WHO III opioids, the presence/absence of a neuropathic pain component; see Table 2 ).
23-29
Two open-label, 12-week, phase 3b studies investigated the effectiveness of tapentadol PR for the treatment of severe chronic OA knee pain 23 or LBP with or without a neuropathic pain component 24 in patients inadequately managed with WHO I or WHO II analgesics or with no regular analgesic treatment. WHO II analgesics were discontinued before initiation of tapentadol PR; WHO I and co-analgesics were maintained. Mean reductions in pain intensity from baseline to week 6 (primary endpoint) were significant: À3.4 AE 2.1 points (OA) 23 and À2.8 AE 2.1 points (LBP) 24 (both P < 0.0001; LOCF) and independent of prior weak opioid experience. In LBP patients, baseline pain À3.4 (P < 0.0001), at week 12: 31 neuropathic pain symptoms also significantly improved over the course of the study. Nausea was the most frequently reported side effect in both studies (13% 23 and 21% 24 ). Tapentadol PR significantly improved state of health, anxiety and depression, and quality of life of the patients in the OA study. 23 At the end of the study, the majority of patients (92%) were satisfied with treatment, and 69.6% rated their condition as "very much" or "much" improved. Open-label tapentadol PR treatment in LBP significantly increased quality of life regardless of type of pain (nociceptive or mixed) but with numerically greater improvements in patients with a neuropathic component to their pain. 24 This is an interesting finding, because neuropathic pain is often more severe with more severe comorbidities and poorer quality of life. 30 More than half of the patients (59.3%) rated their sleep quality as "good" or "excellent" at the end of tapentadol PR study treatment. Direct rotation from prior WHO III opioids to equianalgesic ratios of tapentadol PR could be achieved without loss of pain relief in patients with severe chronic knee OA pain 25 or severe chronic LBP with or without a neuropathic component 26 who had responded to previous treatment with strong opioids but did not tolerate the medication. Pain intensity was significantly reduced from baseline, and side effects observed with the previous strong opioid regimen declined over time. Patients with OA pain showed significant improvements in functional status, health status, and the SF-36 physical component score over the study period (P < 0.0001). 25 At study endpoint of the LBP study, mean (AESD) EQ-5D health status index score had increased from baseline by 0.16 AE 0.26 (P < 0.0001), both mean physical and mental component scores of the SF-36 had increased by 3.8 AE 7.9 and 5.1 AE 10.6, respectively (both P < 0.0001), and mean HADS anxiety and depression scores were significantly reduced (P < 0.005). 26 None of the patients had rated their satisfaction with previous strong opioid treatment better than "fair" (study inclusion criterion). After 12 treatment weeks, 82.8% were satisfied with tapentadol PR ("good," "very good," or "excellent").
Anticonvulsants are frequently used in combination therapy for severe chronic low back pain. 32 The calcium channel a 2 -d ligand pregabalin is recommended as a first-line medication for neuropathic pain 33 and has shown synergistic antihypersensitive activity in a rat model of neuropathic pain when combined with tapentadol. 34 A combination of the 2 medications might thus be beneficial in the treatment of neuropathic or mixed chronic pain. The combination of tapentadol PR and pregabalin was compared to tapentadol PR monotherapy with maximum permitted tapentadol doses in severe chronic LBP with a neuropathic component in a phase 3b study. 27 Following a 3-week open-label titration to 300 mg/day tapentadol PR, patients were randomized to daily doses of either 500 mg tapentadol PR or 300 mg tapentadol PR/300 mg pregabalin. Only patients with stable doses of 300 mg tapentadol PR, a ≥ 1-point reduction in pain intensity from baseline, a pain intensity score of ≥ 4 at randomization, and good tolerability of the analgesic were included in the 8-week double-blind phase. Analgesic effectiveness of tapentadol PR was noninferior to that of the combination therapy (LS mean difference [95% CI], À0.066 [À0.57, 0.43]; P < 0.0001; LOCF). Neuropathic pain scores significantly decreased from baseline and from randomization in both groups (P < 0.0001). Compared to baseline, SF-12 physical component score, anxiety, depression, and health status all significantly improved in both groups (Table 3) . Gastrointestinal tolerability was better under combination therapy, but CNS tolerability was better under tapentadol PR monotherapy despite the maximum permitted doses of 500 mg, which were higher than generally prescribed in routine clinical practice (< 300 mg daily). Tapentadol PR monotherapy seems to be a viable alternative to combination treatment.
Tapentadol PR and the WHO III opioid oxycodone/ naloxone PR were compared in a phase 3b/4, openlabel, randomized, 12-week study in patients with severe chronic LBP with a neuropathic component who had been pretreated with nonopioids.
28, 29 The 2 primary study endpoints were assessed using the per-protocol study population; both assessed changes from randomization visit (baseline) to final evaluation at the end of continuation period or at the time of discontinuation. The primary effectiveness endpoint was the change in average pain intensity (as assessed during the last 3 days prior to baseline and endpoint); to establish noninferiority of tapentadol PR to oxycodone/naloxone PR, the upper limit of the 2-sided 97.5% exact repeated confidence interval (RCI) for the treatment difference (tapentadol PR minus oxycodone/naloxone PR) had to be < 1.3 (noninferiority margin). Additionally, the exact RCI was the basis for switching from noninferiority testing to superiority testing as a confirmatory analysis (in line with criteria defined by EMA guidance 35 ). Noninferiority of tapentadol PR to oxycodone/naloxone PR regarding the primary tolerability-related endpoint (change in bowel function as determined by the Patient Assessment of Constipation Symptoms [PAC-SYM] 36 total score) was established if the upper limit of the 2-sided 97.5% RCI for the treatment difference was less than the noninferiority margin of 0.7. These analyses were adjusted for the group-sequential study design and multiplicity to guarantee overall control of type I error rate (2.5% one-sided). LS mean (SE) changes in pain intensity from baseline to final evaluation were À3.7 (0.25) in the tapentadol PR group (P < 0.001) and À2.7 (0.26) in the oxycodone/naloxone PR (P < 0.001) group. Tapentadol PR was noninferior to oxycodone/naloxone PR (97.5% RCI À1.820, À0.184; P < 0.001). The RCI also showed confirmatory evidence of superiority for tapentadol PR compared with oxycodone/naloxone PR (P = 0.003). However, it should be noted that the early discontinuation rate of patients in the oxycodone/naloxone PR group was nearly twice as high compared to tapentadol PR (62.5% vs. 33.8%), a fact that renders the statement regarding superiority less robust. LS mean (SE) changes in PAC-SYM total score from baseline to final evaluation were 0.07 (0.06) for tapentadol PR (P = 0.235) and 0.14 (0.06) for oxycodone/naloxone PR (P = 0.022). The 97.5% RCI was À0.259, 0.121 (P < 0.001), also showing noninferiority of tapentadol PR. There were significant reductions in neuropathic pain-related symptoms in both the painDETECT 30 and NPSI 31 scores under both treatments. Changes were, however, significantly greater for tapentadol PR for both the painDETECT score (P = 0.002) and NPSI score (P < 0.001). Figure 2 shows the painDETECT results. Gastrointestinal side effects occurred with similar frequency between the groups during the overall treatment period (44.6% for tapentadol PR, 51.6% for oxycodone/ naloxone PR), but the incidences of constipation (15.4% vs. 25.8%; P = 0.045) and vomiting (7.7% vs. 16.4%; P = 0.036) were significantly lower for tapentadol PR. Improvementsin healthstatus, anxiety and depression, and quality of life were also significantly greater for tapentadol PR (see Table 3 ), and significantly more patients under tapentadol PR (54.3% vs. 29.6% for oxycodone/naloxone PR; P < 0.001; LOCF) rated their overall condition as "much improved" or "very much improved." In summary, tapentadol PR provided significant pain relief and markedly improved quality of life and functionality in the treatment of moderate-to-severe chronic OA pain and LBP not only in patients with previous treatment failure but also in patients responding to previous WHO III opioids but tolerating treatment poorly. Pain relief was attained for nociceptive pain and in the presence of a neuropathic component. Efficacy was at least comparable to oxycodone/naloxone PR, with significantly fewer incidences of constipation and vomiting for tapentadol PR. Study results suggest that tapentadol PR monotherapy with higher Comparison between both medications in favor of tapentadol PR: *P = 0.01; † P < 0.017; ‡ P = 0.032; § P = 0.011. Data are mean AE standard deviation 27 or least squares mean difference from baseline to final evaluation AE standard error of the mean. 29 EQ-5D, EuroQoL-5 Dimension health survey; SF, short form; HADS, Hospital Anxiety and Depression Scale; ns, not significant. dosing might be a viable alternative to combination therapy with pregabalin.
POOLED ANALYSES
In order to establish efficacy and tolerability of tapentadol PR in larger patient populations and/or to evaluate secondary endpoints in more detail (for which the primary studies were not powered), studies with a similar design were pooled for further analysis. [37] [38] [39] [40] A pooled analysis included data from 3 randomized, double-blind, placebo-and oxycodone CR-controlled, phase 3 studies in moderate-to-severe chronic OA pain or LBP (Afilalo et al., 13 Buynak et al., 15 and NCT00486811). 37 It showed that, based on the change in mean pain intensity from baseline for the overall 12-week maintenance period, tapentadol PR was noninferior to oxycodone CR (test for 50% retention of oxycodone CR to placebo effect: P < 0.001). The LS mean difference (95% CI) for tapentadol PR vs. oxycodone CR (LOCF) was 0.2 (0.01, 0.04), indicating a greater pain reduction in tapentadol PR as compared to oxycodone CR (P = 0.037 for superiority testing). Similar results were observed using the following methods of imputation: baseline observation carried forward (BOCF), worst observation carried forward, and modified BOCF (Figure 3) . 41 Pain relief under tapentadol PR was achieved regardless of baseline pain intensity, prior opioid intake, gender, or body mass index (BMI) of the patients. 38 Tapentadol PR was also associated with significantly greater improvements in quality of life compared to oxycodone CR in the EQ-5D and the SF-36 physical and mental component scores (all P < 0.001). 37 The safety data of the pooled analysis showed a significantly lower overall incidence of gastrointestinal disorders for tapentadol PR patients (42.8% vs. 65.6% for oxycodone CR; P < 0.001). 37 Treatment withdrawal was more common in the oxycodone CR group (61.7% vs. 43.5% for tapentadol PR); these patients discontinued the treatment significantly earlier than patients receiving placebo or tapentadol PR (both P < 0.001).
A further pooled analysis additionally included data from a 1-year, open-label, oxycodone CR-controlled tolerability study in moderate-to-severe chronic LBP or OA pain 14 and found a lower overall incidence of TEAEs, gastrointestinal TEAEs, and pruritus for tapentadol PR compared to oxycodone CR. 39 Figure 4 shows the most common gastrointestinal and nervous system disorder TEAEs (≥ 5%) for all treatment arms. Incidences of constipation (1.7 times), nausea (1.8 times), and vomiting (2.6 times) were higher under oxycodone CR treatment; tapentadol PR was also associated with a smaller increase in constipation symptom severity as determined by the PAC-SYM questionnaire. Incidences of serious TEAEs were low (placebo 1.3%, tapentadol PR 3.3%, oxycodone CR 3.7%). The most common TEAEs leading to study withdrawal under tapentadol PR were dizziness (3.6%), nausea (3.4%), and vomiting (2.8%).
Data of the 2 similarly designed painful DPN studies mentioned above 16, 19 have also been assessed in a pooled Figure 3 . Better analgesic effectiveness of tapentadol PR compared to oxycodone CR based on the least squares mean difference (LSMD and 95% CI) for the change in pain intensity (11-point numerical rating scale) from baseline for the overall 12-week maintenance period using different imputation methods. Based on a pooled analysis from 3 randomized, double-blind, phase 3 studies of similar design in patients with moderate-to-severe chronic low back pain or osteoarthritis pain (tapentadol PR n = 975, oxycodone CR n = 996). 13, 15 BOCF, baseline observation carried forward; CI, confidence interval; CR, controlled release; LOCF, last observation carried forward; PMI, placebo mean imputation; PR, prolonged release; WOCF, worst observation carried forward. Reprinted from S anchez del Aguila et al. 41 with permission from Elsevier.
analysis. 40 Pain relief was significantly better for tapentadol PR than for placebo (LS mean difference À1.14 [95% CI À1.435 to À0.838]; P < 0.001; LOCF), and rates of patients with ≥ 30% improvement or ≥ 50% improvement from start of open-label titration to week 12 of double-blind treatment were significantly higher in the tapentadol PR group (both P ≤ 0.005). Significant differences in favor of tapentadol PR were also observed for quality of life and health status. Gastrointestinal disorders and nervous system disorders were the most common side effects during the open-label titration phase and during the double-blind maintenance phase in both treatment groups. During maintenance, 34.7% of patients under tapentadol PR reported gastrointestinal TEAEs (placebo 17.8%), 20% stated nervous system disorder TEAEs (placebo 12.8%), and 15.3% had psychiatric disorders (placebo 9%). Nausea (16.9%), vomiting (9.4%), and dizziness and diarrhea (both 7.5%) were the most common single TEAEs under tapentadol PR.
In summary, these pooled analyses confirm the good efficacy and safety profile of tapentadol PR for larger patient cohorts with the following indications: painful OA, LBP, or painful DPN. Pain relief was at least comparable to oxycodone CR, with additional analyses indicating superiority; the tolerability profile was also favorable, with better gastrointestinal tolerability than oxycodone CR.
META-ANALYSES
In addition to the pooled analyses described above, efficacy, safety, and tolerability of tapentadol PR were assessed by systematic reviews. [42] [43] [44] [45] A direct comparison between tapentadol PR and oxycodone CR for the management of severe chronic pain was based on 4 head-to-head trials for pain intensity changes and 3 trials for responder rates. 42 Changes in pain intensity (À2.64, 95% CI: À4.84, À0.44) and 30% and 50% responder rates were all statistically significant in favor of tapentadol PR. Similarly, differences between both analgesics were statistically significant in favor of tapentadol for change in pain intensity, 30% and 50% pain relief, and improvement of quality of life in patients with moderate-tosevere chronic pain (this analysis included both PR and immediate release [IR] formulations). At the time of this review (literature search up to November 2010), no head-to-head trials between tapentadol and WHO III opioids except for oxycodone were available. The authors therefore employed a network meta-analysis. This type of analysis permits an indirect treatment comparison of multiple medications that have not been directly compared in randomized studies. 46 Limitations of such an analysis might include heterogeneity between the included studies, differences in outcome reporting, and different quality of the studies; evidence from an indirect analysis thus needs to be interpreted with caution. However, this indirect analysis provides a first assessment in the absence of head-to-head comparisons.
Reductions in intensity of moderate-to-severe chronic pain were significantly higher under tapentadol compared to morphine and hydromorphone treatment, whereas there was a trend in favor of fentanyl and oxymorphone compared to tapentadol. 42 Gastrointestinal side effects and treatment discontinuations due to adverse events were significantly less frequent under tapentadol than under fentanyl, hydromorphone, morphine, and oxymorphone. A second network meta-analysis compared the PR formulations of tapentadol and oxycodone/naloxone in chronic pain. 43 Analgesic efficacy was not significantly different between the 2 treatments, whereas the reduction in PAC-SYM total score was statistically significant in favor of oxycodone/naloxone PR. However, the study Figure 4 . Most common treatmentemergent adverse events for tapentadol PR, oxycodone CR, and placebo in the treatment of moderate-to-severe chronic low back pain or osteoarthritis pain. Pooled analysis of three 15-week, doubleblind, placebo-and active-controlled studies and a 1-year, open-label, active-controlled safety study. 39 Study population: n = 1,874 for tapentadol PR, n = 1,224 for oxycodone CR, n = 993 for placebo.
populations compared in this analysis were quite different (the oxycodone/naloxone population included primarily opioid-pretreated patients, whereas the tapentadol population had more than 50% opioid-na€ ıve patients). Thus, it is not surprising that the results are in contrast to a head-to-head trial in nonopioid-pretreated patients that showed at least comparable analgesic effectiveness for tapentadol PR and also noninferiority to oxycodone/naloxone PR in the change in PAC-SYM total score from baseline as described above.
28,29
The efficacy and safety of tapentadol PR for chronic moderate-to-severe musculoskeletal pain (knee OA pain or LBP) was determined by 2 meta-analyses comparing the analgesic to placebo and to oxycodone CR (Cochrane Review). 44 Four randomized controlled trials were included: 2 were judged to be of low, 2 of high bias. Tapentadol PR was associated with a 0.56-point better reduction in pain intensity compared to placebo and a 0.24-point better reduction than oxycodone CR. The tolerability and safety profile was more favorable for tapentadol PR than for oxycodone CR. Evidence was considered moderate because heterogeneity was significant for most efficacy and safety outcomes (the number of included studies was small, albeit the studies themselves comprised a relatively large number of patients), and withdrawal rates were high. The authors concluded that the overall clinical benefit of tapentadol PR in moderate-to-severe chronic musculoskeletal pain shown in randomized controlled trials was, as in other opioid trials, relatively small.
A Cochrane Review including 4 randomized controlled trials (1,029 patients) assessed analgesic efficacy and tolerability of tapentadol PR in moderate-to-severe cancer-related pain. 45 The studies were of moderate or small size and different designs; data pooling and statistical analysis were thus not feasible. Analgesic efficacy and side effects were considered comparable between tapentadol PR, oxycodone CR, and morphine CR. In summary, most of these meta-analyses show comparable pain relief between tapentadol PR and WHO III opioids and at least comparable tolerability. However, design limitations need to be considered when evaluating the findings.
ROUTINE CLINICAL PRACTICE DATA
Noninterventional Studies
The majority of the over 10,000 patients observed in routine clinical practice (average age > 60 years) suffered from severe musculoskeletal pain (> 80% low back pain, 30% to 45% with painful osteoarthritis of knee or hip [multiple answers permitted]) and had a pain duration of more than 6 months. Other causes of pain were DPN, stroke/trauma, cancer, and postherpetic neuralgia (PHN). Patients were treated by general practitioners, internists, orthopedists, neurologists, or pain specialists; most (> 90%) were receiving long-term analgesic treatment prior to initiation of tapentadol PR. Main reasons for switching were insufficient pain relief and insufficient quality of life. Table 4 provides details of the five prospective, noninterventional studies which were all carried out in Germany. [47] [48] [49] [50] [51] [52] [53] All studies collected data over a 3-month observation period; 12-month data are additionally available from one study. 49 Tapentadol PR was initiated mainly with 50 mg twice daily (two-thirds of the patients) or 100 mg twice daily (15% to 25% depending on the study) depending on previous pain medication and pain intensity. Mean daily doses were between 192 and 287 mg at the end of the observation. Treatment over the 3-month observation period resulted in significant pain relief; significant improvements in pain-related impairments of functionality and daily activities, sleep, and quality of life; and reductions in additional long-term analgesics in all studies; tapentadol PR was also effective under longterm administration of up to 12 months ( Figure 5 ). 49 Functionality of patients with severe chronic LBP and OA pain improved for all items on German LBP and OA functionality questionnaires, thus indicating increased independence of the patients. 48 Patients were successfully switched from oxycodone/naloxone 50 and other WHO III opioids 47 using tapentadol PR doses well under the maximum permitted 500 mg (average 228 47 and 253 mg 50 ). Over the 12-month treatment period, daily doses remained relatively stable after initial dose adjustments (average 273 mg), resulting in further improvements in pain intensity following the marked reductions during the first 3 treatment months (see Figure 5 ). 49 Tapentadol PR was generally well tolerated, with adverse event incidences between 2.9% and 21.5% under 3-month treatment and 9% under long-term treatment. Nausea was the most frequent adverse drug reaction.
Case Reports
Preliminary evidence that tapentadol PR may be beneficial in the management of phantom limb pain has been shown in a case series in patients with upper or lower extremity phantom pain. 54 Patients received daily tapentadol doses of up to 500 mg. Pain intensity could be reduced by 4 to 6.5 points (visual analog scale 0 to 10) in 4 patients; the fifth patient had an increase in sleep duration from 2 to 5 hours and a 30% reduction in pain attacks. Only 1 patient reported side effects (dizziness and fatigue).
In summary, tapentadol PR is an effective and welltolerated short-and long-term treatment of severe chronic pain under routine clinical practice conditions. It might also be beneficial in the management of phantom limb pain.
PRACTICAL CONSIDERATIONS FOR PAIN TREATMENT IN ROUTINE CLINICAL PRACTICE
Guideline for Use of Opioid-Containing Analgesics
The use of opioid-containing analgesics in short-and long-term management of chronic nonmalignant pain has been investigated in numerous studies but is still controversially discussed. 44, [55] [56] [57] [58] [59] To provide guidance to the general practitioner in Germany, the available literature was analyzed and summarized in an interdisciplinary evidence-and consensus-based S3 guideline (LONTS, long-term opioid use in noncancer pain). This document recommends indications and contraindications for opioid-containing analgesic treatment (≥ 4 weeks); the 2008 version has just been updated.
60
The guideline recommends opioid-containing analgesics as an option for short-term treatment (4 to 12 weeks) of chronic LBP and of chronic pain due to OA, DPN, and PHN. Long-term treatment (≥ 3 months) can be considered in patients with clinically relevant pain relief and/or improvement in functionality, experiencing good tolerability. This treatment should be regularly assessed and should be combined with nonpharmacological treatment options; therapy should include defining realistic individual treatment targets together with the patient. There was also a consensus in preference of prolonged release or long-acting opioid-containing analgesics.
Dosing and Safety of Tapentadol PR
The following chapter provides some information about dosing and safety aspects of tapentadol PR. Detailed information regarding practical considerations and clinical safety particulars for the use of tapentadol PR in the clinical setting can be found in the most recent approved Summary of Product Characteristics 11 and a recent review.
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Tapentadol PR has an easy and reliable titration schedule. Recommended daily starting doses for opioidna€ ıve patients are 50 mg twice daily, which can be increased in increments of 50 mg twice daily every 3 days to achieve adequate analgesia.
11 Routine clinical practice data showed mean daily tapentadol PR doses between 192 and 287 mg, [47] [48] [49] [50] [51] [52] [53] which is markedly lower than the maximum recommended dose of 500 mg/day. Treatment opportunities might be missed when adequate dosages are not attained because dose escalation ended too soon. This should be avoided and should be explained to the patient at an early stage to assure their continued participation in pain management measures. Table 5 shows the tapentadol starting dose recommendations to achieve equianalgesic dosing in patients switching from previous opioid therapy. These depend on the type and daily dose of the previous medication. Conversions are based on standard conversion factors for morphine. Gradual tapering of previous opioid therapy is recommended. Many patients affected by moderate or severe chronic pain are elderly; treatment challenges for this patient group include frequent comorbidities, and thus polypharmacy with possible drug-drug interactions and an increased risk for side effects. Tapentadol PR has a low potential for pharmacokinetic drug-drug interactions. It is a single enantiomer and has no active metabolites. Interactions related to cytochrome P450 activity or plasma protein binding capacity are unlikely, 62 and clinically relevant pharmacokinetic interactions with commonly used medications such as paracetamol, naproxen, acetylsalicylic acid, metoclopramide, probenecid, and omeprazole were not observed.
11 Tapentadol exposure (pharmacokinetic data) was similar for younger patients (19 to 43 years) and elderly subjects (65 to 78 years) 11 ; dose adjustments are thus normally not required. However, as for all opioid analgesics, dose titration should be cautious and slow in the latter patient group. Tapentadol PR showed significantly better gastrointestinal tolerability in the elderly (≥ 75 years) than oxycodone CR, both for incidences of gastrointestinal TEAEs and early treatment withdrawal because of these TEAEs. 63 However, as pharmacokinetic and pharmacodynamic changes occur with advancing age, possible impairments in renal and hepatic function need to be taken into account. In general, dose adjustments are not required for mild or moderate renal or mild hepatic impairment; in case of moderate hepatic dysfunction, treatment should be initiated at the lowest available dose and only once every 24 hours.
11 Tapentadol PR is not recommended for patients with severe renal or hepatic impairment. Abrupt discontinuation of opioid treatment might result in withdrawal symptoms as a sign of physical dependence. Following patients under tapentadol PR treatment for up to 2 years showed a low incidence of opioid withdrawal following abrupt discontinuation.
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The majority of the patients (90.7%) assessed with the Clinical Opiate Withdrawal Scale (COWS) 64 ≥ 5 days following treatment cessation had not experienced opioid withdrawal; mild or moderate withdrawal was reported by 8.7% and 0.6%, respectively. In the subgroup of patients previously receiving tapentadol PR for 1 year, 88.2% did not experience opioid withdrawal following treatment cessation in the second year. It is recommended, however, to gradually taper doses to prevent withdrawal symptoms.
11
As tapentadol PR activates l-opioid receptors, it has a potential for abuse and addiction, which needs to be considered when prescribing the medication to patients with a perceived increased risk for misuse, abuse, addiction, or diversion.
11 However, results from recent studies with the IR formulation suggest that abuse and diversion rates for tapentadol are low.
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In summary, tapentadol PR has a good safety profile with a low potential for pharmacokinetic drug-drug interactions. It is a well-tolerated treatment option for elderly patients and can normally be administered without dose adjustments in this patient population.
CONCLUSIONS
In contrast to other centrally acting analgesics, tapentadol PR combines 2 modes of action (l-opioid agonism and noradrenaline reuptake inhibition) in a single molecule, allowing for high analgesic potency against different pain mechanisms and-owing to the opioidsparing effect-a better tolerability profile compared to WHO III opioids. Noradrenaline reuptake inhibition is thought to be particularly useful in chronic pain conditions whenever a neuropathic pain component cannot be excluded.
Evidence for the effectiveness and tolerability of tapentadol PR in a broad range of chronic pain conditions-particularly whenever a neuropathic pain component cannot be excluded-has been provided by the clinical development program of randomized controlled phase 3 studies and is supported by further phase 3, 3b, or 3b/4 studies. Since market launch in 2010, observational studies have also confirmed the benefits of the medication for chronic pain management in routine clinical practice. Head-to-head studies with WHO III opioids such as oxycodone CR and oxycodone/naloxone PR showed at least comparable pain relief in the treatment of moderate-to-severe musculoskeletal pain. Rotation from poorly tolerated WHO III opioids to tapentadol PR provided effective pain relief and better symptom control for OA knee pain and LBP. Functionality, health status, and quality of life also improved under tapentadol PR treatment. The treatment was generally well tolerated, with a more favorable gastrointestinal tolerability profile compared to tested WHO III opioids. Effective and well-tolerated longterm treatment for up to 2 years under stable dosages also suggests tapentadol PR as a treatment option for the long-term management of moderate-to-severe chronic pain, if opioid therapy is indicated. This is supported by a good safety profile and no evidence of acquired tolerance from the long-term data so far collected.
